Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

Status unconfirmed · Phase 4

Conditions studied: Eczema, Atopic Dermatitis

In brief

The study is trying to answer the following question: "Can we use non-invasive imaging to evaluate the response of atopic dermatitis (eczema) to Dupixent (dupilumab)?"

Key facts

Study ID

NCT05265234

Run by

OptiSkin Medical

People needed

15

Starts

2022-03-01

Expected to finish

2024-03-01

Last updated by the study team

2022-03-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥18 years of age
• Atopic dermatitis (AD) affecting ≥10% body surface area (BSA) at baseline
• IGA score ≥3, on the IGA scale of 0-4 at baseline
• Eczema Area and Severity Index (EASI) score of ≥16 at baseline

You may not qualify if…

• Prior treatment with Dupilumab (REGN668/SAR231893)
• Treatment with TCS or topical calcineurin inhibitors (TCI) within 2 weeks before the baseline visit
• Bodyweight <30 kg (65lb) at Baseline
• Known or suspected immunodeficiency including human immunodeficiency virus (HIV) infection
• Pregnancy, breastfeeding or planning to become pregnant or breastfeed during the study

Where it is running

• OptiSkin Medical — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.